Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Curr Pharm Biotechnol ; 21(5): 390-402, 2020.
Article in English | MEDLINE | ID: mdl-31793418

ABSTRACT

BACKGROUND: Peripheral neuropathy can significantly impact the quality of life for those who are affected, as therapies from the current treatment algorithm often fail to deliver adequate symptom relief. There has, however, been an increasing body of evidence for the use of cannabinoids in the treatment of chronic, noncancer pain. The efficacy of a topically delivered cannabidiol (CBD) oil in the management of neuropathic pain was examined in this four-week, randomized and placebocontrolled trial. METHODS: In total, 29 patients with symptomatic peripheral neuropathy were recruited and enrolled. 15 patients were randomized to the CBD group with the treatment product containing 250 mg CBD/3 fl. oz, and 14 patients were randomized to the placebo group. After four weeks, the placebo group was allowed to crossover into the treatment group. The Neuropathic Pain Scale (NPS) was administered biweekly to assess the mean change from baseline to the end of the treatment period. RESULTS: The study population included 62.1% males and 37.9% females with a mean age of 68 years. There was a statistically significant reduction in intense pain, sharp pain, cold and itchy sensations in the CBD group when compared to the placebo group. No adverse events were reported in this study. CONCLUSION: Our findings demonstrate that the transdermal application of CBD oil can achieve significant improvement in pain and other disturbing sensations in patients with peripheral neuropathy. The treatment product was well tolerated and may provide a more effective alternative compared to other current therapies in the treatment of peripheral neuropathy.


Subject(s)
Analgesics, Non-Narcotic/therapeutic use , Cannabidiol/therapeutic use , Drug Carriers/chemistry , Lower Extremity/innervation , Neuralgia/drug therapy , Oils/chemistry , Administration, Cutaneous , Adult , Aged , Analgesics, Non-Narcotic/administration & dosage , Cannabidiol/administration & dosage , Chronic Pain , Cross-Over Studies , Double-Blind Method , Female , Humans , Male , Microglia/metabolism , Quality of Life , Receptor, Cannabinoid, CB2/metabolism , Treatment Outcome
2.
Curr Pharm Biotechnol ; 18(5): 360-364, 2017.
Article in English | MEDLINE | ID: mdl-28524000

ABSTRACT

BACKGROUND: Up to 25% of diabetic patients will develop a diabetic foot ulcer. Chronic wounds such as diabetic foot ulcers often fail to heal with conventional therapies. In recent years, it has been identified that chronic wounds are usually associated with elevated level of matrix metalloproteinases (MMPs). Doxycycline, a cheap tetracycline antibiotic, has been shown to inhibit MMPs both in vitro and in vivo independent of its antimicrobial property. METHODS: We undertook a search through PUBMED for peer-reviewed research literature with doxycycline, chronic wound, diabetes, MMPs as key words. RESULTS: Seventy papers were included in the review. This review identified doxycycline is a very promising drug to be used in patients with diabetic foot ulcers because higher efficacy even in a very low dosage, little side effects in a lower dosage, inhibition of MMP as well as prevention/treatment of infection in the ulcers, beneficial to cardiovascular complications and cheap to manufacture. CONCLUSION: In this review, we provide an overview of the roles of MMPs in the pathogenesis of chronic wounds and explore the potential application of doxycycline as a treatment option in managing chronic wounds such as diabetic foot ulcers.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Diabetic Foot/drug therapy , Doxycycline/therapeutic use , Matrix Metalloproteinase Inhibitors/therapeutic use , Wound Healing/drug effects , Diabetic Foot/enzymology , Humans , Matrix Metalloproteinases/metabolism , Wound Healing/physiology
3.
Cancer Lett ; 394: 43-51, 2017 05 28.
Article in English | MEDLINE | ID: mdl-28254411

ABSTRACT

Melanoma is the leading cause of death among all skin cancers and its incidence continues to rise rapidly worldwide in the past decades. The available treatment options for melanoma remain limited despite extensive clinical research. Melanoma is an immunogenic tumor and great advances in immunology in recent decades allow for the development of immunotherapeutic agents against melanoma. In recent years, immunotherapy utilizing cytokines has been particularly successful in certain cancers and holds promise for patients with advanced melanoma. In this review, an overview of the current status and emerging perspectives on cytokine immunotherapy for melanoma are discussed in details. Such a study will be helpful to unveil the mysterious mask of cytokine-based immunotherapy for melanoma.


Subject(s)
Antineoplastic Agents/therapeutic use , Cytokines/therapeutic use , Immunotherapy/methods , Melanoma/drug therapy , Skin Neoplasms/drug therapy , Animals , Antineoplastic Agents/immunology , Antineoplastic Agents/metabolism , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cytokines/immunology , Cytokines/metabolism , Humans , Melanoma/immunology , Melanoma/metabolism , Melanoma/pathology , Molecular Targeted Therapy , Signal Transduction/drug effects , Skin Neoplasms/immunology , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
4.
Cancer Lett ; 373(2): 156-63, 2016 Apr 10.
Article in English | MEDLINE | ID: mdl-26826523

ABSTRACT

Interleukin-11 (IL-11) is a member of the glycoprotein-130 (GP-130) cytokines that utilizes the GP-130 signaling pathway shared by other cytokines of the same family. Traditionally regarded as an anti-inflammatory cytokine, IL-11 also demonstrates its role as a proinflammatory cytokine, suggesting its complex role in immune response. In recent years, IL-11 has an emerging role in various inflammation-associated cancers. In this review, we aim to discuss IL-11 signaling pathway, to explore the role of IL-11 in immunity and various cancers, and to provide a therapeutic perspective of strategies utilized to interfere IL-11 signaling in cancer cells.


Subject(s)
Interleukin-11/physiology , Neoplasms/immunology , Animals , Humans , Immunity , Interleukin-3/physiology , Mechanistic Target of Rapamycin Complex 1 , Multiprotein Complexes/physiology , Phosphatidylinositol 3-Kinases/physiology , Proto-Oncogene Proteins c-akt/physiology , STAT3 Transcription Factor/physiology , Signal Transduction , TOR Serine-Threonine Kinases/physiology
SELECTION OF CITATIONS
SEARCH DETAIL
...